查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933908

系統性自體發炎性疾病治療藥物市場（依藥物類別、作用機轉、給藥途徑、通路及最終使用者分類）－全球預測，2026-2032年

Systemic Autoinflammatory Diseases Drug Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，系統性自體發炎性疾病治療市場價值將達到 10.4 億美元，到 2026 年將成長至 11.2 億美元，到 2032 年將達到 18.2 億美元，複合年成長率為 8.24%。

關鍵市場統計數據
基準年 2025 10.4億美元
預計年份：2026年 11.2億美元
預測年份 2032 18.2億美元
複合年成長率 (%) 8.24%

本書權威地介紹了用於治療系統性自體發炎性疾病的藥物，重點闡述了當前臨床挑戰、診斷障礙以及指導藥物研發和相關人員參與的策略要務。

系統性自體發炎性疾病的治療是一個不斷發展的前沿領域，其特徵是臨床表現型多樣、診斷路徑複雜，且存在從症狀管理到長期緩解疾病等諸多未滿足的需求。這種現狀促使藥物研發人員、臨床醫生和支付方提出了一系列多學科需求，包括加速開發可靠的診斷演算法、完善分層治療方案，以及使臨床試驗終點與有意義的、以患者為中心的療效指標相一致。這些因素凸顯了在新型藥物和仿單標示外用藥的整個生命週期中整合證據產生的重要性。

深入分析了改變系統性自體發炎性疾病領域的科學、監管和商業性變化，以及加速在整個治療過程中採用新治療方法的趨勢。

系統性自體發炎性疾病領域正經歷著變革性的轉變，這一轉變涵蓋了科學發現、監管環境和商業性應用等各個面向。細胞激素生物學的進展以及對不同發炎路徑檢驗的驗證，已將白細胞介素-1、白細胞介素-6、Janus激酶和腫瘤壞死因子-α等靶點從實驗候選藥物轉變為臨床可操作的機制。這些科學發現有助於更精準地對患者進行分層，並為聯合治療和序貫療法開闢了道路，從而能夠同時應對急性加重和慢性發炎。

評估2025年美國累積關稅對治療系統性自體發炎性疾病藥物生產商的供應鏈、定價和跨境商業策略的影響

2025年，美國關稅政策的累積變化為系統性自體發炎性疾病治療藥物的全球供應鏈環境引入了新的變數，影響了價值鏈上各相關人員的採購、分銷和定價策略。製造商正在重新評估其採購基礎並實現供應商多元化，以降低關稅風險，同時確保對溫度敏感的複雜生物製藥和無菌注射劑的持續供應。這些調整凸顯了區域製造能力和靈活的契約製造關係的重要性，因為它們能夠吸收關稅相關的成本波動。

關鍵細分洞察揭示了藥物類別、作用機制、給藥途徑、分銷管道和終端用戶環境如何影響治療策略和患者療效。

清晰的細分為臨床開發、商業化路徑和患者需求提供了策略框架。檢驗不同藥物類別之間的差異，我們發現白細胞介素-1抑制劑（如阿那白滯素、卡那單抗和Rilonacept）主要針對抑制自體發炎性疾病的急性發作，強調短間隔給藥策略和減少急性治療。Janus白細胞介素-6受體阻斷劑（如沙拉利單抗和托珠單抗）則提供了一種靶向細胞激素的替代療法，用於持續控制全身性發炎。 Janus激酶抑制劑（如Baricitinib、託法替尼和Upadacitinib）具有口服給藥的優勢，並有可能實現廣泛的全身性免疫調節。同時，腫瘤壞死因子抑制劑（如Adalimumab、Etanercept和Infliximab）擁有豐富的真實世界安全性數據，是控制慢性發炎的重要對照藥物。

區域洞察：識別美洲、歐洲、中東和非洲以及亞太市場在臨床應用模式、支付方行為和監管細微差別方面的差異

區域趨勢持續影響美洲、歐洲、中東和非洲以及亞太地區的研發和商業化策略，每個地區都有其獨特的法規環境、支付者和臨床應用環境。儘管美洲地區臨床醫生對生物製藥有利於生物製劑的推廣應用，但支付方的審查重點在於成本效益和能夠證明其價值超越症狀管理的真實世界療效。從指南認可到獲得廣泛的支付方覆蓋，需要強力的衛生經濟學證據和相關人員的積極參與，以期在降低急性醫療成本和減少長期併發症方面取得成效。

從策略層面深入分析領先生物製藥開發公司的競爭定位、產品線重點、合作方式和商業化模式。

在系統性自體發炎性疾病治療領域，各公司在藥物發現、臨床開發和商業化的各個階段都制定了獨特的策略方針。主要企業正投資於針對已驗證的細胞激素路徑的差異化科學和技術，同時積極拓展檢驗並探索聯合用藥策略，以最大限度地提高臨床效益。競爭優勢越來越依賴於進行頭對頭試驗或真實世界比較研究，以證明新藥相對於現有治療方法的療效、安全性和價值。

為行業領導者提供實用建議，以最佳化轉化醫學、監管和市場進入領域的研發優先排序、商業性執行和協作方式。

產業領導者可以採取多項有針對性的舉措，以促進系統性自體發炎性疾病治療藥物的研發、可及性和長期永續性。首先，應優先考慮基於生物標記的患者分層和適應性試驗設計，以提高獲得具有臨床意義的終點指標的可能性，並促進與監管機構的對話。這種方法將縮短研發週期，並產生與臨床醫生和支付方直接相關的證據。其次，應投資於真實世界證據庫和核准後研究，以證實藥物的長期安全性和健康經濟效益，從而提出更具說服力的報銷提案。

一份透明的調查方法概述，詳細介紹了資料來源、相關人員訪談、證據綜合以及用於得出策略結論和見解的分析框架。

本研究將採用結構化、可重複的調查方法，整合一手與二手證據，兼顧研究深度與實際應用價值。資料來源包括同儕審查文獻、監管文件、臨床指南聲明和匿名化的真實世界證據，並輔以對臨床醫生、支付者、製造商和供應鏈專業人員的訪談。所有證據均根據預先設定的納入標準進行評估，以確保其具有時效性和臨床有效性。

一份關於策略意義、持續挑戰和優先行動的權威綜合報告，供相關人員參考，以推進系統介導的自身發炎性疾病的治療和商業性成功。

這些結論總結了相關人員在系統性自體發炎性疾病領域中應遵循的策略意義。科學進步已明確了可操作的靶點，並拓展了治療選擇，但要實現持續的臨床應用，還需要在實際應用環境中，在對照試驗之外，獲得更多證據。監管和報銷環境正在不斷演變，更加重視可驗證的價值和適應性證據的生成，這要求各方共同投資於核准後數據和相關人員。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 系統性自體發炎性疾病治療市場（依藥物類別分類）

  • IL-1抑制劑
    • 阿納金拉
    • 卡那單抗
    • Rilonacept
  • 白細胞介素-6受體阻斷劑
    • Sarilumab
    • 托珠單抗
  • JAK抑制劑
    • Baricitinib
    • 託法替尼
    • Upadacitinib
  • TNF抑制劑
    • Adalimumab
    • Etanercept
    • Infliximab

9. 系統性自體發炎性疾病治療藥物市場（依作用機轉分類）

  • 白細胞介素-1阻斷
  • 白細胞介素-6受體阻斷
  • Janus激酶抑制
  • 腫瘤壞死因子α抑制劑

第10章 依給藥途徑分類的系統性自體發炎性疾病治療市場

  • 靜脈輸液
  • 口服
  • 皮下注射

第11章 系統性自體發炎性疾病治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終使用者分類的系統性自體發炎性疾病治療市場

  • 診所
  • 居家照護
  • 醫院
  • 專業醫療中心

第13章 各地區系統性自體發炎性疾病治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 系統性自體發炎性疾病治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國系統性自體發炎性疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國系統性自體發炎性疾病治療市場

第17章：中國系統性自體發炎性疾病治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring LLC
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grifols SA
  • Horizon Therapeutics plc
  • Ipsen SA
  • Johnson & Johnson（Janssen Biotech）
  • Merck & Co. Inc.
  • Novartis AG
  • Novimmune SA
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • UCB SA
Product Code: MRR-C36616F699BB

The Systemic Autoinflammatory Diseases Drug Market was valued at USD 1.04 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, with a CAGR of 8.24%, reaching USD 1.82 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.04 billion
Estimated Year [2026] USD 1.12 billion
Forecast Year [2032] USD 1.82 billion
CAGR (%) 8.24%

An authoritative introduction to systemic autoinflammatory disease therapeutics, mapping current clinical challenges, diagnostic hurdles, and the strategic imperatives guiding development and stakeholder engagement

Systemic autoinflammatory diseases present an evolving therapeutic frontier defined by heterogeneous clinical phenotypes, complex diagnostic pathways, and unmet needs that span symptom control to long-term disease modification. The landscape drives an interdisciplinary set of imperatives for drug developers, clinicians, and payers: to accelerate reliable diagnostic algorithms, to refine stratified treatment approaches, and to align clinical trial endpoints with meaningful patient-centered outcomes. These factors increase the importance of integrated evidence generation throughout the life cycle of new and repurposed agents.

As translational science advances, stakeholder expectations shift toward demonstrating durable clinical benefit, favorable safety profiles in chronic use, and real-world value that supports reimbursement. Concurrently, clinical care pathways are adapting to accommodate biologics and small molecules with differing administration modalities and monitoring requirements. This dynamic requires a more sophisticated commercial playbook that integrates health economics, provider education, and patient support to enable uptake. Transitioning from theoretical efficacy to sustained clinical adoption will require coordinated efforts across regulatory science, payer dialogue, and clinical guideline development.

Consequently, organizations entering this space must prioritize cross-functional alignment, invest in evidence that resonates with specialists and generalists, and design supply chain and distribution plans that support flexible access models. In sum, the introduction to this therapeutic area highlights both the scientific progress and the strategic complexity companies must address to achieve durable clinical and commercial success.

A deep analysis of transformative scientific, regulatory, and commercial shifts altering the systemic autoinflammatory disease landscape and accelerating novel modality adoption across care pathways

Transformative shifts in the systemic autoinflammatory disease landscape are unfolding across scientific discovery, regulatory frameworks, and commercial execution. Advances in cytokine biology and the validation of discrete inflammatory pathways have repositioned targets such as interleukin-1, interleukin-6, Janus kinases, and tumor necrosis factor alpha from experimental candidates to clinically actionable mechanisms. These scientific clarifications enable more precise patient stratification and the potential for combination or sequential therapeutic regimens that address both acute flares and chronic inflammation.

Regulatory pathways are concurrently evolving to accommodate adaptive trial designs, surrogate endpoints tied to biomarker resolution, and conditional approvals that demand robust post-authorization evidence. These changes create opportunities for accelerated access but also place a premium on well-designed real-world evidence programs and proactive regulatory engagement. From a commercial standpoint, payers are increasingly focused on outcomes-based contracting and total cost of care, prompting manufacturers to demonstrate not only clinical efficacy but also durable reductions in hospitalizations, steroid use, and downstream complications.

Finally, shifts in care delivery models-such as decentralized clinical trials and digital monitoring-are reshaping patient identification and long-term follow-up. Taken together, these scientific, regulatory, and commercial inflections are catalyzing novel go-to-market architectures and collaborative partnerships aimed at shortening time-to-adoption while managing long-term value delivery.

An assessment of cumulative United States tariff impacts in 2025 on systemic autoinflammatory therapeutics supply chains, pricing dynamics, and cross-border commercial strategies for manufacturers

In 2025, cumulative tariff policy changes in the United States introduced new variables into the global supply chain environment for systemic autoinflammatory therapeutics, influencing procurement, distribution, and pricing strategies for stakeholders across the value chain. Manufacturers are reassessing sourcing footprints and supplier diversification to mitigate tariff exposure while maintaining continuity for complex biologics and sterile injectable formulations that require temperature-controlled logistics. These adjustments underscore the strategic importance of regional manufacturing capabilities and flexible contract manufacturing relationships that can absorb tariff-related cost volatility.

Payers and health systems are responding by intensifying scrutiny of total delivered cost, which includes duties and import-related fees. This heightened attention incentivizes manufacturers to present transparent cost and value narratives, to explore localized inventory strategies, and to negotiate distribution agreements that optimize landed cost without compromising product integrity. In parallel, procurement teams are increasingly evaluating the balance between onshore production premiums and the stability benefits they deliver, particularly for high-priority parenteral agents.

Moreover, tariffs can accelerate shifts toward alternative administration routes or formulations that simplify distribution complexity. These operational and commercial responses together demonstrate that tariff-driven pressures extend beyond immediate cost impacts; they refract through supply chain design, commercialization timing, and strategic choices about where to invest for resilience. Stakeholders that proactively integrate tariff scenarios into planning will better preserve launch momentum and maintain patient access amid evolving trade environments.

Key segmentation-driven insights illuminating how drug class, mechanism of action, administration route, distribution channels, and end-user settings shape therapeutic strategies and patient outcomes

Segmentation clarity provides a strategic framework to align clinical development with commercial pathways and patient needs. Examining drug class distinctions highlights that interleukin-1 inhibitors-including agents such as anakinra, canakinumab, and rilonacept-tend to focus on rapid control of autoinflammatory flares and may emphasize short-interval dosing strategies and acute care reduction. Interleukin-6 receptor blockade options like sarilumab and tocilizumab offer alternative cytokine-targeted approaches that can be positioned for persistent systemic inflammation control. Janus kinase inhibitors such as baricitinib, tofacitinib, and upadacitinib represent oral modality advantages with potential for broader systemic immunomodulation, while tumor necrosis factor inhibitors such as adalimumab, etanercept, and infliximab remain important comparators for chronic inflammatory control with extensive real-world safety data.

Mechanism of action segmentation underscores differentiation opportunities tied to interleukin-1 blockade, interleukin-6 receptor blockade, Janus kinase inhibition, and tumor necrosis factor alpha inhibition, each presenting distinct biomarker profiles and monitoring needs that influence payer and clinician acceptance. Route of administration considerations-spanning intravenous infusion, oral administration, and subcutaneous injection-drive different patient support models and adherence dynamics, with implications for site-of-care economics and patient preference.

Distribution channel and end-user segmentation further refine go-to-market approaches by recognizing the roles of hospital pharmacies, online pharmacies, and retail pharmacies in enabling access, and by acknowledging clinical settings such as clinics, home care, hospitals, and specialty centers as primary touchpoints for treatment initiation and ongoing management. Together, these segmentation lenses inform targeted clinical development decisions, differentiated messaging, and tailored access strategies that resonate with specific stakeholders.

Regional insights identifying differentiated clinical adoption patterns, payer behaviors, and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics continue to shape development and commercialization strategies in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting unique regulatory, payer, and clinical adoption environments. In the Americas, clinician familiarity with biologics and established specialty pharmacy infrastructures support adoption, but payer scrutiny emphasizes cost-effectiveness and real-world outcomes that demonstrate value beyond symptomatic control. Transitioning from guideline recognition to broad payer coverage requires robust health-economic evidence and stakeholder engagement that addresses both acute care savings and long-term morbidity reduction.

In Europe, Middle East & Africa, regulatory heterogeneity and varying reimbursement mechanisms necessitate region-specific evidence packages and adaptive pricing strategies. Centralized approvals in some European jurisdictions coexist with localized reimbursement assessments that prioritize comparative effectiveness and budget impact analysis. In the Middle East and Africa, infrastructure and access variability underscore the importance of partnerships that support cold-chain logistics, clinician training, and patient support mechanisms.

The Asia-Pacific region presents a spectrum ranging from highly advanced markets with rapid adoption potential to emerging markets where affordability and distribution networks are the primary constraints. Local manufacturing partnerships, tailored pricing, and culturally appropriate patient support programs often accelerate uptake. Across all regions, early alignment with regional key opinion leaders, investment in real-world evidence generation, and flexible commercial models that reflect provider and payer needs will be decisive factors in successful geographic rollouts.

Strategic company-level insights that examine competitive positioning, pipeline focus, partnership approaches, and commercialization models among leading biopharmaceutical developers

Companies operating in the systemic autoinflammatory therapeutics space are defining distinct strategic approaches across discovery, clinical development, and commercialization. Leading developers invest in differentiated science that targets validated cytokine pathways while simultaneously pursuing label-expanding indications and combination strategies to maximize clinical benefit. Competitive positioning increasingly hinges on generating head-to-head or real-world comparative evidence that clarifies relative efficacy, safety, and value versus established therapies.

Partnership strategies are also central to competitive advantage; alliances with contract manufacturing organizations, specialty pharmacy providers, and diagnostic developers enable faster scale-up and improved patient access. Firms that prioritize integrated launch models-aligning commercial analytics, medical affairs, and payer engagement early in development-are better positioned to negotiate value-based arrangements and demonstrate system-level savings.

At the same time, commercialization models are evolving toward hybrid distribution and support programs that reduce administrative friction for prescribers and patients. Organizations that strengthen their evidence generation through longitudinal observational studies and pragmatic trials add credibility in payer dialogues and can accelerate adoption. Ultimately, corporate success in this space will reflect the ability to translate mechanistic differentiation into measurable clinical outcomes, to secure pragmatic access pathways, and to execute distribution strategies that deliver consistent, patient-centered care.

Actionable recommendations for industry leaders to optimize development prioritization, commercial execution, and collaborative approaches across translational, regulatory, and market-access domains

Industry leaders can pursue several targeted actions to strengthen development, access, and long-term sustainability in systemic autoinflammatory therapeutics. First, prioritize biomarker-driven patient segmentation and adaptive trial designs that increase the probability of demonstrating clinically meaningful endpoints and facilitate regulatory dialogue. This approach shortens development cycles and yields evidence that is directly relevant to clinicians and payers. Second, invest in real-world evidence infrastructures and post-authorization studies that confirm long-term safety and health-economic benefits, enabling more compelling reimbursement propositions.

Third, design flexible commercial models that account for varied routes of administration and site-of-care preferences; these models should integrate patient support services that improve adherence and reduce administrative burdens for prescribers. Fourth, fortify supply chains through geographic diversification and strategic manufacturing partnerships to mitigate tariff and logistics risks and to preserve product integrity. Fifth, cultivate payer relationships early by co-developing outcome measures and contracting frameworks that reflect shared risk and reward.

Collectively, these recommendations emphasize the need for integrated planning across R&D, regulatory affairs, market access, and commercial operations. Adhering to these priorities will help organizations navigate complexity, accelerate responsible adoption, and ultimately deliver improved outcomes for patients living with systemic autoinflammatory conditions.

A transparent research methodology overview detailing data sources, stakeholder interviews, evidence synthesis, and analytical frameworks applied to derive strategic conclusions and insights

This research synthesizes primary and secondary evidence through a structured, reproducible methodology that balances depth with practical relevance. Data inputs include peer-reviewed literature, regulatory filings, clinical guideline statements, and anonymized real-world evidence sources, complemented by targeted stakeholder interviews with clinicians, payers, manufacturers, and supply chain experts. The evidence base was evaluated against predefined inclusion criteria to ensure contemporary relevance and clinical validity.

Analytical frameworks integrated mechanism-of-action mapping, segmentation analysis across drug class and administration routes, and scenario planning for regulatory and trade policy shifts. Qualitative insights were derived from semi-structured interviews and thematic coding to surface consensus views on unmet needs and adoption barriers, while quantitative descriptive analyses were used to characterize distribution channel dynamics and site-of-care economics. Validation steps included cross-checking interview findings against public regulatory decisions and clinical guideline updates to ensure alignment with current practice.

The methodology emphasizes transparency through documentation of assumptions, source provenance, and analytic boundaries. Where uncertainty exists, sensitivity analyses clarify alternative pathways and implications for stakeholders. This approach supports robust interpretation of findings and facilitates targeted follow-up analyses tailored to specific strategic questions.

A conclusive synthesis of strategic implications, persistent challenges, and priority actions that stakeholders should consider to advance systemic autoinflammatory disease care and commercial success

The conclusion synthesizes the strategic implications for stakeholders navigating the systemic autoinflammatory disease landscape. Scientific advances have clarified actionable targets and enabled a growing set of therapeutic options, yet durable clinical adoption depends on evidence that extends beyond controlled trials into pragmatic, real-world settings. Regulatory and reimbursement environments are evolving in ways that reward demonstrable value and adaptive evidence generation, requiring coordinated investments in post-approval data and stakeholder engagement.

Operational considerations-such as manufacturing resilience, distribution flexibility, and patient support program design-remain central to preserving access and maintaining launch momentum. Tariff and trade policy dynamics add another layer of complexity that influences sourcing decisions and landed cost calculations. From a commercial perspective, success will favor organizations that integrate mechanism-based differentiation with pragmatic distribution strategies and payer-oriented evidence programs.

Ultimately, the pathway to improved outcomes for patients and sustainable commercial performance demands cross-functional alignment, transparent value demonstration, and agile execution. Stakeholders that act on these priorities will be better equipped to deliver meaningful therapeutic advances while navigating the systemic, regulatory, and commercial challenges that characterize this therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Systemic Autoinflammatory Diseases Drug Market, by Drug Class

  • 8.1. Il-1 Inhibitors
    • 8.1.1. Anakinra
    • 8.1.2. Canakinumab
    • 8.1.3. Rilonacept
  • 8.2. Interleukin-6 Receptor Blockade
    • 8.2.1. Sarilumab
    • 8.2.2. Tocilizumab
  • 8.3. Jak Inhibitors
    • 8.3.1. Baricitinib
    • 8.3.2. Tofacitinib
    • 8.3.3. Upadacitinib
  • 8.4. Tnf Inhibitors
    • 8.4.1. Adalimumab
    • 8.4.2. Etanercept
    • 8.4.3. Infliximab

9. Systemic Autoinflammatory Diseases Drug Market, by Mechanism Of Action

  • 9.1. Interleukin-1 Blockade
  • 9.2. Interleukin-6 Receptor Blockade
  • 9.3. Janus Kinase Inhibition
  • 9.4. Tumor Necrosis Factor Alpha Inhibition

10. Systemic Autoinflammatory Diseases Drug Market, by Route Of Administration

  • 10.1. Intravenous Infusion
  • 10.2. Oral Administration
  • 10.3. Subcutaneous Injection

11. Systemic Autoinflammatory Diseases Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Systemic Autoinflammatory Diseases Drug Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals
  • 12.4. Specialty Centers

13. Systemic Autoinflammatory Diseases Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Systemic Autoinflammatory Diseases Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Systemic Autoinflammatory Diseases Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Systemic Autoinflammatory Diseases Drug Market

17. China Systemic Autoinflammatory Diseases Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Biogen Inc.
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. CSL Behring LLC
  • 18.11. Eli Lilly and Company
  • 18.12. GlaxoSmithKline plc
  • 18.13. Grifols SA
  • 18.14. Horizon Therapeutics plc
  • 18.15. Ipsen SA
  • 18.16. Johnson & Johnson (Janssen Biotech)
  • 18.17. Merck & Co. Inc.
  • 18.18. Novartis AG
  • 18.19. Novimmune SA
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi S.A.
  • 18.24. Swedish Orphan Biovitrum AB
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. UCB SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ANAKINRA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CANAKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RILONACEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SARILUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOCILIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BARICITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ETANERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-1 BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JANUS KINASE INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR ALPHA INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. GCC SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. NATO SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTERLEUKIN-6 RECEPTOR BLOCKADE, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA SYSTEMIC AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)